Mergers & Acquisitions ·
Ensysce Biosciences reported a net loss of $2.6 million for the second quarter ended June 30, 2026, compared to a $1.7…
ENSCWEnsysce Biosciences, Inc.
Ensysce Biosciences reported a net loss of $2.6 million for the second quarter ended June 30, 2026, compared to a $1.7 million loss in the prior year period. The company completed its acquisition of Cy Biopharma on August 6, 2026, adding CY200, an Orphan Drug-designated candidate for Complex Regional Pain Syndrome, as its lead pipeline asset. This transaction was supported by private placement financings totaling up to $77 million, including a $38.6 million initial tranche and a potential second tranche of the same amount triggered by clinical milestones. Concurrently, Ensysce raised approximately $21.5 million through the sale of Series C non-voting convertible preferred stock led by Ally Bridge Group. These financings provide cash runway into late 2027. The company also advanced its PF614-MPAR program with a third-year NIDA grant award and continues enrollment in pivotal Phase 3 trials for PF614. Ensysce Biosciences is a clinical-stage biotechnology company developing neuroplastogenic therapies and novel opioids for pain management.